Target intelligence / Profile preview

Proteasome 20S subunit beta type

Molecular classification
Enzyme
01

Overview

The proteasome 20S subunit beta type refers to the β subunits (β1 through β7) of the 20S core proteasome, a barrel-shaped complex of four heptameric rings (α7-β7-β7-α7) responsible for degrading ubiquitinated proteins into peptides via threonine protease activity. The catalytic β subunits (β1, β2, β5) feature N-terminal propeptides that are autocatalytically cleaved during maturation, exposing the active Thr1 residue; β1 exhibits caspase-like (post-acidic) activity, β2 trypsin-like (basic residues), and β5 chymotrypsin-like (hydrophobic residues). These subunits assemble stepwise with chaperones like PAC1-4 and POMP, enabling protein homeostasis, cell cycle regulation, and antigen processing. Note: "Proteasome 20S subunit beta type" is nonspecific (generic class, not a single isoform like PSMB5); specify isoform (e.g., "Proteasome 20S subunit beta 5") for precise targeting. Drugs primarily target catalytic sites in β1/β2/β5 for cancer therapy.

Other names
20S proteasome β subunitproteasome β subunitPSMB (various isoforms like PSMB1, PSMB2, PSMB5)β1 (caspase-like)β2 (trypsin-like)β5 (chymotrypsin-like)
02

Mechanism of action

Inhibition of chymotrypsin-like activity (β5), inhibition of trypsin-like activity (β2), inhibition of caspase-like activity (β1), and covalent binding to N-terminal threonine.

03

Biological functions

Protein degradationProteolysis
04

Disease associations

CancerNeurodegenerative diseaseImmune response
05

Safety considerations

Peripheral neuropathyGastrointestinal toxicityThrombocytopenia
06

Interacting drugs

Bortezomib

2 more in the full profile.

Beyond the preview

Go deeper on Proteasome 20S subunit beta type.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Proteasome 20S subunit beta type.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call